Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenABCWY 4-year antibody persistence and booster extension study in adolescents and young adults
2016-004420-29Phase 2
- Sponsor
- GSK
- Start
- Dec 2016
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of Meningococcal ABCYW vaccine in meningococcal disease (3 arms), sponsored by GSK. Primary endpoints: hSBA geometric mean titers against meningococcal serogroups A, C, W, Y and serogroup B test strains and Antibody persistence thresholds.
02
Drugs
Meningococcal ABCYW vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2016-004420-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004420-29.